Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacodynamics of CSL311 (Trabikibart) in Asthma and Healthy Volunteers
NCT04082754Phase 1Completed
- Sponsor
- CSL Limited
- Start
- Nov 2019
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of trabikibart in asthma (14 arms), sponsored by CSL Limited. Primary endpoints: Treatment-Emergent Adverse Events at Day 114 and Related Treatment-Emergent Adverse Events at Day 114. Started Nov 2019; status: completed.
02
Drugs
trabikibart
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04082754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082754.